Rezolute Stock Plunges After Phase 3 sunRIZE Trial Misses Endpoints
Rezolute's Phase 3 sunRIZE trial for ersodetug failed to meet primary and key secondary endpoints in congenital hyperinsulinism. Shares collapsed about 85-90% on December 11, 2025, and a securities law firm is investigating potential claims.
Rezolute, Inc. (NASDAQ: RZLT) shares fell sharply on December 11, 2025, after topline results from its Phase 3 sunRIZE clinical trial for ersodetug, its lead drug candidate for treating congenital hyperinsulinism, failed to meet both primary and key secondary endpoints. The highest dose showed reductions in hypoglycemia events that were not statistically significant versus placebo.
During intraday trading, RZLT collapsed from levels near its prior day close of around $10.94 to an intraday low near $0.90, representing an approximate 85–90% drop, and trading was halted under Nasdaq's volatility controls. A securities law firm, Faruqi & Faruqi, LLP, announced it is investigating potential claims against Rezolute on behalf of investors who suffered significant losses.